Cytotoxicity Assay Services of Radiolabeled Compounds
In vitro cytotoxicity testing at Rdcthera - a comprehensive package for radiopharmaceuticals. Equipped with state-of-the-art technology and scientific know-how, Rdcthera supports the development of and safety assessment for radiolabeled compounds. With these services, we are trying to fulfill the requirements of the pharmaceutical industry by providing reliable and reproducible, informative data to move projects in research and development forward.
Introduction to Cytotoxicity Assays
Cytotoxicity assays have been described as one of the most significant screens that could relate the compounds' potential to provoke toxic effects on living cells. In radiopharmaceuticals, such studies become essential as radioactive substances will provide different actions on cellular functions. This means that the performance of in vitro cytotoxicity assays will allow one to foresee undesired effects, optimize dosage, and raise the general safety profile related to radiopharmaceuticals before going to in vivo studies or clinical trials.
Fig. 1. Cytotoxicity analysis by MTT assay. (Beg S, et al., 2022)
Our Cytotoxicity Assay Services
We have a whole array of cytotoxicity assays that gauge various cellular metabolic activities and different specific biomarkers for radiopharmaceuticals and radiolabeled compounds.
| Cytotoxicity Assays |
Description |
|
The cell viability/proliferation is estimated by colorimetric MTT or MTS. |
|
It has flow cytometry and molecular techniques for the detection and identification of programmed cell death. |
|
Inflammatory cell death pathways are measured to explain compound-specific effects. |
|
Monitoring levels of ROS and their related antioxidant responses. |
|
Measure intracellular glutathione as an indicator for oxidative-stress conditions and redox balance. |
|
Apply Gluc/Gal assays to Mitochondrial toxicity assessment. |
Our Analytical Methodologies of Cytotoxicity Assays
Our state-of-the-art methodologies are designed to deliver precise and reliable data. We employ,
- Flow Cytometry
- High-Content Imaging
- Colorimetric and Fluorometric Assays
- Molecular Biology Techniques
Data and Insights from Our Services
Using our cytotoxicity assay services, detailed data and insights would be provided to the client, including but not limited to the following
- Volume details of cell viability and proliferation profiles
- Apoptotic and necrotic cell populations
- Levels of markers for oxidative stress and antioxidant capacity
- Intracellular glutathione content quantification and other relevant biomarkers
- Thorough reports with interpretation and recommendations for further studies
Our Expertise and Capabilities
Rdcthera's team includes seasoned scientists and researchers with a lead background in radiopharmaceutical development and toxicology. Capabilities include
- High-Throughput Screening of Large Compound Libraries
- Development of customized assays to suit specific research requirements
- Advanced data analysis and bioinformatics support
- Collaborative approach to ensure client-focused solutions
Our Advantages
- Radiopharmaceutical Expertise
Specialized knowledge in handling and assessing radiolabeled compounds.
Tailor-made solutions for specific project requirements.
Reliable, reproducible, and enabler-insight data to support your informed decisions.
Our customer service and communications throughout make you feel supported through your project.
For more information on anthology cell cytotoxicity assays for radiopharmaceuticals and how we can help advance your research and development projects, please do not hesitate to contact us.
Reference
- Beg S, Malik AK, Ansari MJ, et al. (2022). Systematic Development of Solid Lipid Nanoparticles of Abiraterone Acetate with Improved Oral Bioavailability and Anticancer Activity for Prostate Carcinoma Treatment. ACS Omega. 7(20):16968-16979.
For research use only. Not intended for any clinical use.
Related Service
